Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 13Lymphoma 13Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Hodgkin Disease 5Leukemia 4Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Leukemia, Biphenotypic, Acute 3Burkitt Lymphoma 3Breast Neoplasms 3Recurrence 2Ovarian Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Immunoblastic Lymphadenopathy 2Hemangioma 2Enteropathy-Associated T-Cell Lymphoma 2Stomatitis 1Stomach Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peripheral Nervous System Diseases 1Oral Ulcer 1Neurotoxicity Syndromes 1Neoadjuvant Therapy 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer Patients 1

Interventions

Cyclophosphamide 23Prednisone 16N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Vincristine 11Doxorubicin 11Etoposide 9fludarabine phosphate 8Whole-Body Irradiation 8Mycophenolic Acid 7Lenalidomide 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6Brentuximab Vedotin 6Azacitidine 6Alemtuzumab 6Cyclosporine 5Bortezomib 5romidepsin 4fludarabine 4Tacrolimus 4Rituximab 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4pembrolizumab 3denileukin diftitox 3Transplantation 3Dexamethasone 3Carmustine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Peripheral × Prednisolone × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡